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Epstein-Barr virus (EBV) is the causal agent in the etiology of Burkitt’s lymphoma and nasopharyngeal carcinoma and is also
associated with multiple human malignancies, including Hodgkin’s and non-Hodgkin’s lymphoma, and posttransplantation
lymphoproliferative disease, as well as sporadic cancers of other tissues. A causal relationship of EBV to these latter malignancies
remains controversial, although the episomic EBV genome in most of these cancers is clonal, suggesting infection very early in
the development of the tumor and a possible role for EBV in the genesis of these diseases. Furthermore, the prognosis of these
tumors is invariably poor when EBV is present, compared to their EBV-negative counterparts. The physical presence of EBV in
these tumors represents a potential “tumor-speciﬁc” target for therapeutic approaches. While treatment options for other types
of herpesvirus infections have evolved and improved over the last two decades, however, therapies directed at EBV have lagged.
A major constraint to pharmacological intervention is the shift from lytic infection to a latent pattern of gene expression, which
persists in those tumors associated with the virus. In this paper we provide a brief account of new virus-targeted therapeutic
approaches against EBV-associated malignancies.
1.Introduction
Epstein-Barr virus (EBV) infection is ubiquitous in human
populations worldwide. EBV infection in children and
adolescents usually leads to a self-limiting lytic infection,
designated as infectious mononucleosis (IM) [1, 2]. How-
ever, in immunocompromised individuals, such as those
with X-linked lymphoproliferative disease (XLP) [3, 4], EBV
infections often progress unchecked and are lethal. EBV is
invariably associated with nasopharyngeal carcinoma (NPC)
[5], African Burkitt’s lymphoma (BL) [6], posttransplan-
tation lymphoproliferative disease (PTLD) [7–10], and less
often with a number of other human malignancies such
as Hodgkin’s lymphoma (HD) [11], and non-Hodgkin’s
lymphomas (NHL). In addition, EBV is found in a fraction
of gastric carcinomas [12, 13] and carcinomas of the breast
[14–16]. Although EBV has been identiﬁed in these latter
tumors, it remains controversial whether EBV is causally-
related to their development. Nonetheless, multiple studies
have clearly demonstrated that the presence of EBV in these
tumors confers a poorer prognosis [17–22].
In the mid-Eighties, the technique of random cleavage
of the terminal repeat region of the EBV genome was
employed as a method of identifying clonality of the virus
episome population in infected cells or tissues [23, 24].
During EBV lytic replication (described later), long head-
to-tail concatameric DNA is produced from the circular
episomal DNA, which is then cleaved randomly within the
terminal repeat region by viral-encoded terminase, leading
to the production of virus particles with varying length
of their terminal repeats [25]. Latently infected B-cells,
however, do not produce virus particles and the circularized
EBV episomal genome replicates in coordination with the
division of cellular genome, producing exact copies of the
viral genome in daughter cells. Multiple studies using this
type of analysis clearly demonstrated that the EBV genome
in many of the EBV-associated tumors, such as BL [26], NPC
[23], and HD [11], is clonal in nature, strongly suggesting
thatthesetumorsdevelopedfromasingleprogenitorcellthat
wasalreadyinfectedwithEBV,lendingfurthersupporttothe
concept that EBV may be causally related to the genesis of
many of these tumors.2 Advances in Virology
2. EBV Infection and Replication
EBV transmission usually takes place through the mucosal
secretions of the mouth of an infected individual. Primary
infection of epithelial cells of the oropharynx leads to
active production of virus particles with shedding of the
virus in saliva. Although the EBV-epithelial cell attachment
process is not fully understood, the neighboring B-cells
subsequently become infected via interaction of the EBV
surface protein gp350 with the lymphocyte receptor CD21,
however, such infections are often nonproductive. Active
or “lytic” replication of EBV induces lysis of infected cells
concurrent with production of virus particles, whereas latent
replication of EBV does not. EBV is a member of the gamma
herpesvirus family, with a large 172Kb double-stranded
linearDNAgenomeencodingnearly100genes.Mostofthese
genes are expressed during lytic-phase replication, whereas
only a maximum of eleven viral genes are expressed during
latent-phasereplication.TheuptoelevenEBVgeneproducts
that are expressed in latently infected cells (the number
depends upon the type of latency) include six nuclear anti-
gens (EBNA1, EBNA2, EBNA3A-3B-3C, EBNA-LP), three
latent membrane proteins (LMP1, LMP2A-2B), the BARF0
protein, generated from BART transcripts, and two small
noncoding non-poly-A RNAs (EBER1 and EBER2). Primary
EBVinfectionresultsinstronghumoralandcellularimmune
responses. IgM antibodies against EBV surface protein
(gp350) are easily detectable in the serum during primary
infection, which is then eclipsed by a steady state level of IgG
antibody over the ensuing months and beyond [27].
The symptoms of acute infection, such as IM, sub-
side within few weeks as EBV enters a latent replication
mode. EBV subsequently generates a life-long persistent
infection in all infected individuals. Seroepidemiological
surveys demonstrate that more than 90% of humans are
positive for EBV antibody [28, 29]. The majority of infected
individuals bear cytotoxic T cells directed against the virus,
and at any given time only a small proportion of resting
B cells are latently infected with the virus (one or two in
am i l l i o n )[ 30, 31]. EBV infection of primary human B
lymphocytes in vitro leads to their immortalization and the
development of continuously growing lymphoblastoid cell
lines (LCL) [32]. In a healthy individual, however, a strict
equilibrium between proliferation of EBV-infected B cells
and immune surveillance is maintained [33]. In the setting
of immunodeﬁciencies (whether hereditary or induced),
however, this equilibrium is lost and the resulting unchecked
proliferation of virus-immortalized B cells can then lead to
the development of lymphoma, such as XLP or PTLD.
3. Therapies againstEBV Diseases
Existing therapeutic approaches for EBV-associated diseases
are broadly categorized into three groups, as shown in
Table 1.
3.1. Pharmacological Therapy. Nucleoside-analog anti-her-
pesvirus drugs, such as ganciclovir, acyclovir, or famcyclovir,
are moderately eﬃcient in suppressing virus replication and
Table 1: Available therapies for EBV diseases.
Modalities Classiﬁcation Comments
Drug treatment Acyclovir/ganciclovir
Inhibits virus
replication and induces
cell killing. Eﬀective
only against lytic EBV
infection.
Immunotherapy Vaccination
Recombinant
gp350-based vaccine,
CTL epitope
peptide-based vaccine.
Treatment of disease
Monoclonal antibody
against CD21, anti
CD-20 antibody
(Rituximab);
EBV-speciﬁc cytotoxic T
cells from donor or ex
vivo ampliﬁcation of
CTLs from patients and
infusion back to the
patient.
Virus-directed
approaches
Utilization of
presence of virus in
the tumor
Various cell-killing
strategies that are
dependent on EBV gene
expression.
virus shedding during diseases characterized by acute or lytic
replication of EBV. They are not active in EBV-associated
malignancies,however,becauseinEBV-associatedmalignant
diseasestheEBVmaintainsalatentstateofreplication.These
commonly-used antiviral agents are prodrugs, and require
conversion to their active form by virus-encoded kinases
before they can be eﬀective (see Figure 1). For the Epstein-
Barr virus, however, these viral kinases are expressed only
during lytic replication.
3.2. Immunotherapy. Immunotherapeutic approaches have
been studied in clinical trials for a number of years, with
success in some cases. Normally, the host’s CD4+ and CD8+
cytotoxic T cells and natural killer (NK) cells play an
important role in killing EBV-infected cells during primary
infection. Although EBV can often be cultured from throat
washings of previously infected individual, continuing CTL
immunosurveillance in normal individuals is quite eﬃcient
in controlling subsequent reactivation of EBV infection.
Vaccination with recombinant gp350 viral glycoprotein or
CTL epitope-based peptide has been successful in generating
viral immunity in animal models [34–36]a n dm a yi n
the future prove useful in areas that are endemic for
EBV malignancies (such as China and southeast Asia).
Clinical vaccine trials in healthy individuals demonstrated
the appearance of neutralizing anti-EBV antibodies in
vaccinated individuals [37, 38]. However, the ubiquitous
nature of EBV infection but low incidence of malignancies
arising from the infected individuals makes prevention of
EBV-associated malignancies of lesser importance than the
control of the malignancy once it has occurred. Adoptive
transfer of EBV-speciﬁc CTLs from an EBV-positive donorAdvances in Virology 3
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Figure 1: Schematic diagram of combination therapy approaches
in EBV malignancies. EBV maintains latent replication in tumor
cells and these tumor cells are not susceptible to anti-herpesvirus
prodrugs, such as GCV. In the presence of lytic-phase gene
expression-inducing agents such as butyrate, the latent EBV
expresses thymidine kinase (TK) which converts the prodrug GCV
to GCV-P, which is then converted to the (cytotoxic) triphosphate
form by cellular kinases. During DNA replication, the triphosphate
form of GCV is then incorporated into genomic and viral DNA,
causing chain termination, cell-cycle arrest, and apoptosis of the
EBV-infected cells.
to the transplant recipient has been utilized in a limited
fashion in the treatment of PTLDs and other solid tumors
[39–42]. CTLs may also be isolated from a recipient’s own
lymphocytes, expanded in vitro, and infused back into the
patient [43, 44]. These approaches have provided some
clinicalbeneﬁtincertainhighlyselectedpatients,particularly
in the treatment of PTLD [40, 45, 46]. However, adoptive
transfer of EBV-speciﬁc CTLs has not been as eﬀective in
patients with NPC or HD [47]. This approach is constrained
by the availability of donor lymphocytes, and the long time
requiredfortheinvitroprocessingandexpansionoftheCTL.
Furthermore,therequirementforpriorlymphodepletion for
in vivo CTL expansion is also a major obstacle. Radiation
and chemotherapy-induced lymphodepletion often lead to
multiple unwanted side eﬀects. Recently, CD45 monoclonal
antibodies are being used to induce a short-term lymphode-
pleted environment without unwanted side eﬀects, allowing
subsequent expansion of infused EBV-speciﬁc CTLs [48]. A
recent comprehensive review of EBV-speciﬁc T-cell therapies
currently under investigation is available [49].
4.Virus-TargetedTherapies
In most EBV-associated malignancies, all or nearly all of
the tumor cells contain the viral genome. Furthermore,
Table 2: Virus-directed novel approaches.
Classes Comments Reference
Targeting EBV
episome
Low dose hydroxyurea
treatment
Chodosh et al. [50],
Slobod et al. [51]
Inhibition of EBV
transforming
protein
Antisense RNA against
LMP-1 oncoprotein Kenney et al. [52]
EBV-dependent
expression of
cellular toxins
Expression of
detrimental cellular
proteins through OriP
dependent expression
vector
Hirai et al. [53],
Kenney et al. [54]
Combination
therapy
Induction of EBV lytic
replication + cytotoxic
drugs
Numerous, Listed in
Table 3
at any given time, the number of EBV-infected nontumor
cells present in other physiological compartments of the
host is usually very low, and for B cells is on the order of
one in a million. This provides a unique opportunity to
develop therapeutic strategies utilizing the presence of the
viral genome of EBV in the tumors as an essentially “tumor-
speciﬁc” target. One of the virus-targeted therapeutic strate-
gies is based on the concept that EBV-containing cells will
die if lytic replication can be induced. Other strategies
employ selective expression of toxins in EBV-infected cells
or preventing the function of EBV latent gene products that
are linked to oncogenesis (Table 2). Elimination of episomal
EBV genomes by low dose hydroxyurea treatment has been
shown to decrease the tumorigenic potential of Akata cells
of BL origin, both in vitro and in SCID mice [50]. When
two patients with AIDS-related (EBV-positive) primary
lymphoma of the central nervous system were treated with
low dose hydroxyurea, their median survival compared to
historical controls increased by almost 18 months [51]. The
eﬀectiveness of this approach in a controlled clinical trial,
however, has yet to be evaluated. Expression of antisense
RNA against the EBV LMP-1 protein has been shown
to reduce LMP-1 expression in LCLs and concomitantly
inhibit cell proliferation and stimulate apoptosis [52]. As
EBNA1 is a viral transactivator expressed in all latently
EBV-infected tumor cells and utilizes the OriP promotor
for its activity, several studies have utilized an OriP-based
vector to direct the expression of cellular toxins, such as
driving cytosine deaminase expression (which converts the
prodrug 5-ﬂurocytosine to cytotoxic 5-ﬂurouracil), or the
herpes simplex virus TK, to make the cells susceptible to
nucleoside analog antiviral drugs [53, 54]. Targeted delivery
of these EBV-dependent vectors speciﬁcally to the tumors
cells, however, remains a serious and unresolved challenge.
Themostsigniﬁcantadvancementinvirus-targetedther-
apies for EBV malignancies is undoubtedly the combination
therapy that is based on artiﬁcial induction of EBV lytic-
phase gene expression, followed by exposure of the tumor
cells to anti-herpesvirus drugs. It was established thirty years
ago that induced expression of the herpes simplex virus
TK enzyme renders cells susceptible to prodrugs such as4 Advances in Virology
ganciclovir or acyclovir [55]. Guti´ errez et al. ﬁrst utilized
this approach in EBV lymphoma cells by transfecting a Zta
expression plasmid under the control of an OriP promoter.
This plasmid also expressed HSV-TK. Transfection of this
plasmid in the EBV-positive BL cell line P3HR1 induced
lytic-phase gene expression, and in the presence of ACV,
signiﬁcantly reduced the growth of P3HR1 cells [56]. In
two other studies, adenoviral vectors containing a BZLF1
or BRLF1 expression cassette under the control of the
CMV promoter were used to infect the EBV-positive BL
cell line, an NPC cell line, and an EBV-transformed gastric
carcinomacelllines [57,58].TheBZLF1andBRLF1proteins
both initiate the lytic replication cycle of EBV. In both
of these studies, adenoviral vector-mediated BZLF1 and
BRLF1 expression induced EBV-lytic phase proteins, such
as BMRF1, in all the cell lines tested, whereas the empty
adenovirus vector (expressing only GFP) had no such eﬀect.
When these adenovirus vectors were injected directly into
xenografted tumors in SCID mice induced by the BL or
NPC lines, BZLF1 and BLRF1 expression in the tumors
was readily detected. There was a substantial coincident
reduction of xenograft tumor size in the BZLF1- or BRLF1-
adenovirus vector-injected tumors compared to controls
[58]. The addition of GCV, however, did not appear to
have any additional eﬀects on tumor burden. The authors
speculatedthathighlevelexpressionofEBVimmediate-early
genes, such as BZLF1 or BRLF1, in normal cells could be
toxicandacknowledgedthatthereisnoreliablegenedelivery
system yet available to target only EBV-containing cells [59].
ThemechanismsunderlyinginductionofEBVlyticrepli-
cationoutoflatencyusingchemicalinducerssuchasphorbol
esters (PMA), 5-Azacytidine (5-Aza-C), sodium butyrate,
and other agents have been studied for decades [60–64].
These speciﬁc agents are known to induce or support the
expression of EBV immediate-early genes. In the case of
PMA, this eﬀect is the result of protein kinase C-mediated
activation of the Jun-Fos proteins and their interaction with
AP-1 binding sites on the regulatory elements of the EBV IE
genes [65]. Exposure to 5-Aza-C removes the transcriptional
block on expression of the EBV genome during latency,
caused by extensive CpG methylation [66]. Butyrate facil-
itates reactivation of latent EBV by allowing remodeling of
the chromatin-like structure of the EBV genome, through its
histone deacetylase (HDAC) inhibitory activity [67, 68]. The
recent discovery that butyrate and other HDAC inhibitors
(HDACi) can also induce demethylation and reactivation
of methylated, silenced genes through repression of DNA
methyltransferase 1 DNMT1 [69] may also contribute to
their activity in inducing EBV lytic-phase gene expression.
Combination therapy using a chemical inducer of EBV lytic-
phase gene expression (arginine butyrate) and the anti-
herpesvirus prodrug GCV was ﬁrst tested on lymphoma cells
derived from the EBV-positive lymphoma from a lung trans-
plantation patient [70]. Arginine butyrate exposure induced
the lytic-phase gene and protein TK in these lymphoma cells,
and, in combination with GCV, inhibited the proliferation
of the tumor cells in a dose-dependent manner. This in
vitro activity led to a protocol for treatment of the lung
transplant patient (who was already receiving GCV with
no eﬀect on the lymphoma) with 750mg/kg/day arginine
butyrate therapy for 15 days. The combination therapy was
well tolerated by the patient, as no additional toxicity was
observed. Although the patient eventually succumbed to
an unrelated Aspergillus infection, pathological examination
revealed substantial necrosis of the tumor following the
treatment [70]. This study demonstrated for the ﬁrst time
the feasibility of combination therapy in the treatment of
EBV malignancies in human subjects. Shortly thereafter,
other inducers of EBV lytic replication were investigated in
vitro and also in xenografted EBV tumor models in mice.
Westphal et al. employed γ-radiation or sodium butyrate
t r e a t m e n tt oi n d u c eE B Vl y t i c - p h a s eg e n ee x p r e s s i o ni n
LCLs, BL cells Akata and Jijoye, and in an EBV-transformed
gastric carcinoma cell line AGS [71]. Although the extent
of EBV reactivation was variable within diﬀerent cell lines,
on average, 400cG irradiation induced the immediate-early
BMRF1 protein in all of the lines. Induction of BMRF1 by
sodium butyrate (up to 2.5mM) was inconsistent in this
study, although a combination of butyrate and irradiation
markedly induced BMRF1, irrespective of the cell lines
tested. When xenografted tumors in SCID mice induced by
these EBV-positive cell lines were exposed to a single dose of
γ-radiation (400cG), or were injected intraperitoneally with
500μL of 50mM sodium butyrate, the BMRF1 protein was
induced in the tumors, although less eﬃciently by butyrate
than by γ-irradiation. A subset of the xenografted animals
that were exposed to γ-radiation were also treated with
GCV and followed over a month. Tumors in three out
of four mice in this group did not progress in size. This
study therefore supported the earlier ﬁndings in the clinical
trial that the combination of induction of EBV lytic-phase
proteins and treatment with anti-herpesvirus drugs may be a
useful therapeutic approach.
Based on the results of our previous combination
treatment approach for the EBV lymphoma in a lung
transplant recipient [70], we initiated a phase I/II clinical
trial with ten patients, all of whom had EBV-positive
lymphoid tumors which were refractory to conventional
chemotherapeuticsorradiationtherapy.Thetypesoftumors
in the patients enrolled in the trial included PTLD, B-cell
NHL, cutaneous T-cell lymphomas, T/NK lymphomas, and
HD. The trial design utilized an intrapatient dose escalation
of arginine butyrate combined with a standard dose of GCV.
Preliminary results of this study, published in 2001 [72],
demonstrated that ﬁve out of 10 patients had complete
clinical responses and two additional patients had partial
responses. Complete necrosis of the EBV lymphoma was
noted in two out of the three patients in which pathological
analyses were carried out. Analysis of the patient-derived
tumor cells in culture again conﬁrmed induction of EBV
TK expression and resulting susceptibility to GCV [73].
A complete report of this multicenter multinational trial,
with ﬁve additional patients included, was reported more
recently [74]. Altogether, 10 out of 15 patients, all of whom
had tumors refractory to all conventional therapies, showed
signiﬁcant anti-tumor responses, with 4 complete responses
and 6 partial responses. Although complications from rapid
lysis of the tumors did occur in 3 patients, this studyAdvances in Virology 5
Table 3: Combination therapy approaches in the treatment of EBV malignancies.
Lytic replication inducer Drug Target cells In vivo Reference
DNA methylase transferase inhibitors
5-Azacytidine GCV and
5-bromodeoxyuridine EBV+ and EBV- BL cells None Moore et al. [75]
HDAC inhibitors
Arg-Butyrate GCV LCL from lung
transplant recipient
Single human
patient Mentzer et al. [70]
Arg-Butyrate GCV 10 human
patients Mentzer et al. [76]
Arg-Butyrate GCV 15 human
patients Perrine et al. [74]
Valproic Acid∗
Cisplatin, 5-FU,
Gemcitabine,
Doxorubicin
LCL, gastric
carcinoma-EBV, NPC SCID mice Feng et al. [77]
Na-Butyrate GCV P3HR1 None Ghosh et al. [78]
Radiation
γ-Radiation + Na-butyrate GCV & AZT LCL and BL cell lines SCID mice Westphal et al. [71]
γ-Radiation AZT+GCV LCL-4A1A Nude rats Roychowdhury et al. [79]
B-cell receptor blockade
Rituximab+Dexamethasone GCV AKATA Nude mice Daibata et al. [80]
Proteasome inhibitor
Bortezomib 131I-FIAU BL cell line SCID
xenograft Fu et al. [81]
Other
Cis-platinum, 5-ﬂuorouracil, Taxol GCV Gastric carcinoma, NPC Nude mice Feng et al. [82]
Gemcitabine and Doxorubicin GCV LCL, and BL cell lines SCID mice Feng et al. [83]
demonstrated that the combination of arginine butyrate and
G C Vw a sw e l lt o l e r a t e di nab r o a ds p e c t r u mo fp a t i e n t s .
The maximum tolerated dose of arginine butyrate was found
to be 1250mg/kg/day. This controlled phase I/II trial paved
the way for studies of this combination therapy approach
in larger cohorts. It is also noteworthy that response to
this regimen occurred in patients with multiple diverse
types of lymphomas, including both lymphomas in which
EBV was clearly a causative agent (PTLD), and in tumors
where the etiological role of the virus was less clear (B-cell
NHL, cutaneous T-cell lymphomas, and T/NK lymphomas).
It appears that the presence of the virus in latent form
alone is suﬃcient to render the tumor cells sensitive to this
therapeutic approach. In vitro studies, in which the virus is
artiﬁcially introduced into the tumor cells, have conﬁrmed
this (Ghosh and Faller, unpublished).
Several other studies have investigated the potential
of other lytic-phase gene expression-inducing agents in
preclinical studies, using EBV+ lymphoma cell lines. Some
of these studies also utilized mouse models to test the
reproducibility of their cell culture ﬁndings. DNA methyl
transferase inhibitors, HDACi, radiation therapy, protea-
somal inhibitors, B-cell receptor-blocking antibodies, and
chemotherapeutic drugs were evaluated in these reports.
A list of these studies is presented in Table 3. The studies
all demonstrated varying degrees of activity in the various
model cell lines. The study of Fu et al. [84] included
an interesting variation which utilized an 125I-labeled
nucleoside analogue, 2 -ﬂuoro-2 -deoxy-ß-D-5-iodouracil-
arabinofuranoside(FIAU),tovisualizeantiviralagentuptake
in EBV+ tumors, by specialized CT-imaging. In this study,
EBV lytic-phase gene expression in xenografted EBV+ BL
tumors in SCID mice was induced by the chemotherapeutic
proteasomal inhibitor bortezomib. Biodistribution analyses
indicated preferential accumulation of FIAU in the tumors
of the bortezomib-treated animals by 48–72hr, but not in
the vehicle-treated animals. The experimental radiopharma-
ceutical 131I-FIAU was used in a later study by this group
which demonstrated xenografted EBV-tumor regression in
SCID mice in response to combination treatment with 131I-
FIAU and bortezomib by CT imaging [81].
While the basic concept of combination therapy has been
tested in multiple in vitro studies and animal studies, and
proof-of principle has been documented in the clinical trials,
the optimal pharmacological inducer of EBV lytic-phase
gene expression has not yet been determined. Ideally, this
inducer should be highly active in inducing EBV lytic-phase
genesandshouldhaveexcellentbioavailability.Inourclinical
trial, we demonstrated that butyrate acts as an eﬀective
inducer of EBV lytic replication, and, together with an anti-
herpesvirus drug, inhibits tumor growth and induces tumor
regression [74, 76]. Because of its very short half-life in vivo,
however, butyrate required continuous infusion over several
daysfortherapeuticsynergywithantivirals.Inarecentstudy,6 Advances in Virology
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Figure 2: Cytotoxic activity of various HDACi in the presence of an anti-herpesvirus nucleoside analog prodrug, GCV. Three hundred
thousand P3HR1 cells were exposed to either 40μM GCV or vehicle, and the indicated concentrations of individual HDACi, in a 1mL
volume in 24-well plates, in triplicate. Seventy-two hrs later, 800μL of the media was removed without disturbing the settled cells and
1mL of fresh growth media containing GCV (40μM) was added and the cells, which were cultured for another 72hrs. HDACi studied
included butyrate, valproate, apicidin, largazole and its analogs, MS275, oxamﬂatin, LBH589, SAHA, and Scriptaid. The number above
the HDAC+GCV bar represents the percentage of cells surviving, relative to the cultures exposed to that particular HDAC inhibitor alone
(assigned a value of 100%). Error bars represent standard deviation.Advances in Virology 7
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Figure 3: Eﬀect of HDACi and GCV combination treatment on other EBV-positive lymphoma cells. (a) Eﬀect of combination treatment on
the BL line Daudi. Four hundred thousand cells per ml per well were cultured with 60 μM GCV in the appropriate wells. Assay parameters
were as described in the legend to Figure 2.( b )E ﬀect of combination treatment on the EBV-transformed lymphoblastoid cell line JY. In this
case, 200,000 cells per well were plated in the presence of 60 μM GCV, or vehicle, as indicated. Experiments were repeated a minimum of
three times and error bars represent standard deviation.
we demonstrated that multiple short 6–8hr exposures of
P3HR1 cells to butyrate also eﬃciently induced EBV TK,
and in the presence of GCV inhibited tumor cell growth
[78]. This observation was translated into a clinical protocol
to treat a rituximab-refractory EBV-positive PTLD patient
who had received a cord-blood stem cell transplant for
Hodgkin’s disease [85]. A 5-day infusion of arginine butyrate
and 21 days of GCV/valganciclovir treatment resulted in
complete resolution of 4 out of 6 lesions in this patient, and
decrease in the size of two other lesions. It is also noteworthy
that this patient was symptomatic from EBV, CMV, and
HHV-6 viremia, with very high plasma viral loads, despite
ongoing administration of GCV/valganciclovir. After 1 cycle
ofcombinationtherapy,thesevirallevelsdecreasedbyseveral
logsorfelltoundetectablelevels,andhersymptomsresolved,
suggesting the applicability of this combination approach to
multiple types of viruses in addition to EBV.
InvitrostudieshavedemonstratedthatHDACiarepotent
antiproliferative agents that cause cell-cycle arrest, apoptosis
and/or diﬀerentiation of tumors [86, 87]. Furthermore, their
preferential cytotoxic activity on tumor cells over normal
cells suggested potential anticancer therapeutic application.
In recent years, a number of HDACi have been tested
in clinical trials. In addition, eﬀorts have been made8 Advances in Virology
to develop more potent, or more HDAC class selective,
HDACi. Although HDACi as a class are well-known inducers
of EBV lytic-phase gene expression [88], only butyrate
a n dv a l p r o i ca c i dh a v eb e e nt e s t e df o rt h e i ra c t i v i t yi n
treating EBV malignancies [70, 76, 77]. We have recently
completed studies to test a variety of HDACi of diﬀerent
chemical classes, including some new and highly potent
compounds, for their ability to sensitize EBV-lymphoma
cells to anti-herpesvirus drugs. The HDACi studied included
short-chain fatty acids (butyrate, valproate), hydroxamic
acids (SAHA, oxamﬂatin, LBH589, scriptaid, PDX101),
benzamide (MS275), a cyclic tetrapeptide (apicidin), and
largazoles (originally isolated from marine cyanobacterium).
With the exception of SAHA and PXD101, all of the other
HDACi produced sensitization to GCV, and the combination
caused cytotoxicity in EBV+ lymphoma cells (when used
as a single agent, PDX101 itself exerted a strong cytotoxic
eﬀect on the cells [89, 90]). LBH589, MS275, and synthetic
largazole derivatives were 104 to 105 t i m e sm o r ep o t e n ti n
killing EBV+ lymphoma cells in presence of GCV, compared
to sodium butyrate (Figure 2). The eﬀective concentration
of LBH589 was in the range of 50–100nM, MS275 at 200–
500nM, and largazoles at 100–200nM. The eﬀectiveness
of these HDAC-inhibitory (HDACi) compounds at such
low concentrations makes them potentially applicable as
sensitizers to antiviral therapeutics for the treatment of EBV-
associated lymphomas. Furthermore, butyrate and LBH589
were also found to potently sensitize another BL cell line
(Daudi) and a lymphoblastoid cell line (JY) (Figure 3).
These ﬁndings therefore suggest that that these new and
potent HDACi may provide alternative therapeutic options
to butyrate, in combination with nucleoside antiviral agents,
for the treatment of EBV-associated tumors.
5. Concluding Remarks
EBV-associated malignancies remain a signiﬁcant health
concern worldwide, with particularly higher incidences in
southeast Asia and China. In Western countries, the inci-
denceofEBVmalignancies,andparticularlyPTLD,isalsoon
the rise. The increasing use of solid organ or hematopoietic
transplantation, especially in situations requiring intense
immunosuppression, is most likely a major contributor to
this increase in EBV-lymphomas. Furthermore, as referenced
above, the presence of EBV in the common NHL and HD
lymphomas confers a much poorer prognosis after conven-
tional therapy, demonstrating the need for new therapeutic
approaches.
The presence of EBV in these tumors represents a poten-
tial “tumor-speciﬁc” targeting opportunity for the develop-
ment of new therapeutics. Among all potential therapeutic
avenues explored to date for targeting the virus in EBV-
positive tumors, pharmacological induction of EBV lytic
infection coupled with an anti-herpesvirus agent appears to
be most promising, as a variety of potential virus-inducing
agents (some of which are logs more potent than butyrate)
are now available, as are active and safe antiviral prodrugs.
Furthermore, because a fewof the new HDACi with excellent
pharmacokineticsandpharmacodynamicproﬁlesarealready
“clinical-stage,” they could rapidly be employed in clinical
trials.
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